RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split
By Dr. Matthew Watson
SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (the “Company”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that a 1-for-8 reverse stock split of its outstanding shares of common stock will be effective at 11:59 pm Eastern Time June 16, 2025.
Go here to read the rest:
RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split
Related Post
- Leading Independent Proxy Advisor Glass Lewis Recommends Shareholders Vote the GREEN proxy FOR ALL MediPharm Director Nominees - June 16th, 2025
- GT Biopharma Appoints New Member to its Board of Directors - June 16th, 2025
- Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress - June 16th, 2025
- PolTREG Establishes U.S. Subsidiary Immuthera to Advance International Development Strategy - June 16th, 2025
- Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple... - June 16th, 2025
- Sunset Social Club Opens as West Hollywood’s First Luxury Cannabis Lounge for Members Only - June 16th, 2025
- IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2025 - June 16th, 2025
- 23andMe Reaches Agreement for Sale of Business to TTAM Research Institute Following Final Round of Bidding in Court-Approved Sale Process - June 16th, 2025
- Vaxart Announces Preliminary Results of Annual Meeting of Stockholders - June 16th, 2025
- Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at... - June 16th, 2025
- Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria - June 16th, 2025
- Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R)... - June 16th, 2025
- [Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in... - June 16th, 2025
- Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema... - June 16th, 2025
- Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor - June 16th, 2025
- Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with... - June 16th, 2025
- Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with... - June 16th, 2025
- Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease - June 16th, 2025
- EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL - June 16th, 2025
- Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates - June 3rd, 2025
- Abivax Presents First Quarter 2025 Financial Results - June 3rd, 2025
- Cronos Group Inc. to Speak at the TD Cowen 9th Annual Future of the Consumer Conference - June 3rd, 2025
- Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative... - June 3rd, 2025
- Ardelyx Appoints Mike Kelliher Chief Business Officer and James P. Brady Chief Human Resources Officer - June 3rd, 2025
- Vaxart Announces Adjournment of Annual Meeting of Stockholders - June 3rd, 2025
- Sernova Appoints Jonathan Rigby as Interim Chair - June 3rd, 2025
- Neuronetics Set to Join Russell 2000® and Russell 3000® Indexes - June 3rd, 2025
- Harvard Bioscience Appoints John Duke to Board of Directors - June 3rd, 2025
- Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 3rd, 2025
- Quest PharmaTech Provides Corporate Update - June 3rd, 2025
- Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting - June 3rd, 2025
- Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders - June 3rd, 2025
- Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568 - June 3rd, 2025
- Live from ASCO 2025 | Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral Report - June 3rd, 2025
- Live from ASCO 2025 | Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors - June 3rd, 2025
- argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference - June 3rd, 2025
- Press Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell disease - June 3rd, 2025
- Roche’s Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer - June 3rd, 2025
- Addex Convenes Annual General Meeting 2025 - June 3rd, 2025
- Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025 - May 26th, 2025
- Allogene Therapeutics Announces Participation in Upcoming Investor Conferences - May 26th, 2025
- IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of... - May 26th, 2025
- Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025 - May 26th, 2025
- Syncromune® Inc. Announces Publication of Abstract on SYNC-T® Therapy SV-102 Phase 1 Data for Metastatic Prostate Cancer at ASCO 2025 Annual Meeting - May 26th, 2025
- Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2 - May 26th, 2025
- CHMP recommends EU approval of Roche’s Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer - May 26th, 2025
- MediPharm Labs Cautions Shareholders about Dissident Nominees’ Governance Failures at Check-Cap Ltd. - May 26th, 2025
- Boundless Bio Announces Portfolio Prioritization and Runway Extension - May 26th, 2025
- Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year;... - May 26th, 2025
- AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 - May 26th, 2025
- PMV Pharmaceuticals to Participate at Upcoming Investor Conferences - May 26th, 2025
- Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q - May 26th, 2025
- Zhengye Biotechnology Holding Limited Receives NASDAQ Notice Related to Late Filing of Form 20-F - May 26th, 2025
- IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules - May 26th, 2025
- Polyrizon Announces Receipt of Nasdaq Delisting Notice - May 26th, 2025
- Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant... - May 26th, 2025
- ZLNA – Issuance of shares through set-off of option exercise fee - May 26th, 2025
- Guerbet : Changes in the composition of the Guerbet board of directors. - May 26th, 2025
- Chair of Sernova Biotherapeutics Resigns - May 26th, 2025
- Vaxart Approves Resolutions to Narrow Proposed Reverse Split Range and Proposes Reducing Authorized Shares at Future Stockholder Meeting - May 18th, 2025
- Spectral Medical to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference - May 18th, 2025
- Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day - May 18th, 2025
- Windtree Therapeutics Reports First Quarter 2025 Financial Results and Provides Key Business Updates - May 18th, 2025
- Vivex Biologics, Inc. Executive Chair Nominated for Ernst & Young LLP Entrepreneur of the Year® 2025 Florida Award - May 18th, 2025
- PharmaTher Announces FDA Extends Review Period for Ketamine; New Approval Goal Date August 9, 2025 - May 18th, 2025
- Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study - May 18th, 2025
- Medicines for Poland: Europe Faces a Critical Choice on Medicines and Market Reform - May 18th, 2025
- Conduit Pharmaceuticals Inc. Announces Reverse Stock Split - May 18th, 2025
- BON Announces The Launch Of Its Postbiotic Hypoglycemic Patented Ingredient Product Series And Its Cooperation Agreement - May 18th, 2025
- Transactions of Managers and Closely Associated Persons - May 18th, 2025
- GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase - May 18th, 2025
- Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the... - May 18th, 2025
- TestoPrime Reviews Side Effects (INVESTIGATED) Is This Testosterone Booster Safe? (Ingredients, Results & Where to Buy) - May 18th, 2025
- BlueSphere Bio Appoints Alan Korman, Ph.D. as Chief Scientific Officer - May 18th, 2025
- 75th Annual Regeneron International Science and Engineering Fair Awards Teen Scientists from Around the World More Than $9 Million in 2025 Competition - May 18th, 2025
- Alvotech Announces the Outcome of the Offering in Connection with the Company’s Listing on Nasdaq Stockholm - May 18th, 2025
- Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference - May 18th, 2025
- Tessera Therapeutics Features New Preclinical Data Demonstrating Progress Across its In Vivo Gene Writing™ Programs and Delivery Platform at the... - May 18th, 2025
- Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF... - May 18th, 2025
- Coherus to Report First Quarter 2025 Financial Results on May 12, 2025 - May 6th, 2025
Global News Feed
Comments Off on RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split |
June 16th, 2025
This author published 6272 posts in this site.Share
Comments are closed.
Personalized Gene Medicine
| Mesenchymal Stem Cells
| Stem Cell Treatment for Multiple Sclerosis
| Stem Cell Treatments
| Board Certified Stem Cell Doctors
| Stem Cell Medicine
| Personalized Stem Cells Therapy
| Stem Cell Therapy TV
| Individual Stem Cell Therapy
| Stem Cell Therapy Updates
| MD Supervised Stem Cell Therapy
| IPS Stem Cell Org
| IPS Stem Cell Net
| Genetic Medicine
| Gene Medicine
| Longevity Medicine
| Immortality Medicine
| Nano Medicine
| Gene Therapy MD
| Individual Gene Therapy
| Affordable Stem Cell Therapy
| Affordable Stem Cells
| Stem Cells Research
| Stem Cell Breaking Research